Armata Pharmaceuticals (ARMP) Q3 2024 earnings summary

Executive summary

• Focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, with two lead candidates (AP-PA02 and AP-SA02) in late-stage clinical development targeting chronic pulmonary and acute systemic infections.

• Completed enrollment in two Phase 2 trials (Tailwind for NCFB and diSArm for S. aureus bacteremia) in 2024; topline data expected by end of 2024 (Tailwind) and Q1 2025 (diSArm).

• Received additional $5.3 million grant from MTEC and $5.25 million in non-dilutive funding from the Department of Defense, increasing total award to $21.6 million, supporting clinical development.

• Amended Convertible Credit Agreement and 2023 Credit Agreement in November 2024, extending maturity dates to January 2026.

• Appointed David House as Senior Vice President, Finance.

Financial highlights

• Grant revenue for Q3 2024 was $3.0 million, up 143% year-over-year, and $3.94 million for the nine months, up 31%.

• Operating loss for Q3 2024 was $9.76 million, a 5.6% improvement year-over-year; net loss for Q3 2024 was $5.48 million ($0.15 per share), down from $31.16 million ($0.86 per share) in Q3 2023, aided by a $6.9 million non-cash gain from convertible debt fair value changes.

• Net loss for the nine months ended September 30, 2024 was $21.52 million, a 56% improvement from $49.20 million in the prior year period.

• Cash and cash equivalents were $17.1 million as of September 30, 2024, up from $13.5 million at year-end 2023.

Outlook and guidance

• Existing cash is insufficient to fund operations for the next 12 months; additional capital will be required through equity, debt, or strategic arrangements.

• Topline data from the Tailwind and diSArm studies expected by end of 2024 and Q1 2025, respectively, with pivotal Phase 3 trials planned for 2025.

• Anticipates major value inflection points in 2025 and beyond as clinical milestones are reached.